CAC 40
7 319,79 -26,36 (-0,36 %) Euro Stoxx 50
4 410,36 -8,15 (-0,18 %) Dow Jones
36 052,12 -193,38 (-0,53 %) EUR/USD
1,0827 -0,0058 (-0,53 %) Gold future
2 065,20 -24,50 (-1,17 %) Bitcoin EUR
38 396,39 +1 807,46 (+4,94 %)
MRK Jan 2026 95.000 call
| Clôture précédente | 19,44 |
| Ouverture | 19,44 |
| Offre | 0,00 |
| Vente | 0,00 |
| Prix d’exercice | 95,00 |
| Date d’expiration | 2026-01-16 |
| Var. jour | 19,44 - 19,44 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 34 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
